Cancer Chemotherapy and Pharmacology

, Volume 23, Issue 5, pp 329–330 | Cite as

Severe renal failure following high-dose ifosfamide and mesna

  • Pax H. B. Willemse
  • Paul E. de Jong
  • Job B. Elema
  • Nanno H. Mulder
Original Articles Ifosfamide, Renal Function, Mesna

Summary

A 62-year-old woman developed subacute renal failure after the repeated administration of ifosfamide (IFX), despite its combination with continuous sodium 2-mercaptoethane sulfonate (mesna) infusion. Biopsy findings, the possible underlying mechanism, and the existing literature are discussed.

References

  1. 1.
    Brock N, Pohl J, Stekar J, Scheef W (1982) Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention: III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol 18: 1377Google Scholar
  2. 2.
    Burkert H (1983) Clinical overview of mesna. Cancer Treat Rev 10 [Suppl A]: 175Google Scholar
  3. 3.
    Einhorn LH (1986) VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer Cancer Chemother Pharmacol 18 [Suppl 2]: S45Google Scholar
  4. 4.
    Goren MP, Wright RK, Pratt CB, Horowitz ME, Dodge RK, Viar MJ, Kounar EH (1987) Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res 47: 1457Google Scholar
  5. 5.
    Hilgard P, Herdrich K, Brade W (1983) Ifosfamide-current aspects and perspectives. Cancer Treat Rev 10 [Suppl A]: 183Google Scholar
  6. 6.
    Klein HA, Wickramanayake PD, Löffler T, Hirschmann WD (1980) High dose therapy with cytostatic drugs. Cancer Campaign 4: 291Google Scholar
  7. 7.
    Klein HA, Wickramanayake PD, Coerper C, Christian E (1983) High-dose ifosfamide and mesna as continuous infusion over five days — a phase I/II trial. Cancer Treat Rev 10 [Suppl A]: 167Google Scholar
  8. 8.
    Likes KE, Catchatourian R, Simon LS, Gurwich EL (1978) Cyclophosphamide-induced hemorrhagic cystitis exacerbated by melphalan. Drug Int Clin Pharmacol 12: 432Google Scholar
  9. 9.
    Pohl J (1981) Toxicity, pharmacology and interactions of uromitexan. In: Burkert H, Nagel GA (eds) New experience with the oxazaphosphorines with special reference to the uroprotector uromitexan. Karger, Basel, p 12Google Scholar
  10. 10.
    Sangster G, Kaye SB, Calman KC, Dalton JF (1984) Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity. Eur J Cancer Clin Oncol 20: 435Google Scholar
  11. 11.
    Stuart-Harris RC, Harper PG, Parsons CA, Kaye SB, Mooney CA, Gowing NF, Wiltshaw E (1983) High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 11: 69Google Scholar
  12. 12.
    Van Dyk JJ, Falkson HC, van der Merwe AM, Falkson G (1972) Unexpected toxicity in patients treated with iphosphamide. Cancer Res 32: 921–924Google Scholar
  13. 13.
    Shaw IC, Graham MI (1987) Mesna — a short review. Cancer Treat Rev 14: 67Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Pax H. B. Willemse
    • 1
  • Paul E. de Jong
    • 2
  • Job B. Elema
    • 3
  • Nanno H. Mulder
    • 1
  1. 1.Department of Internal Medicine, Division of Medical OncologyUniversity HospitalGroningenThe Netherlands
  2. 2.Department of NephrologyUniversity HospitalGroningenThe Netherlands
  3. 3.Department of PathologyUniversity HospitalGroningenThe Netherlands

Personalised recommendations